Amir Nashat has spent nearly two decades building biotechnology companies. The first he worked on, Alnylam Pharmaceuticals, pioneered a new way to make genetic medicine. He's since helped advise and nurture at least 16 others, several of which were acquired for hundreds of millions of dollars.
Image: Yujin Kim/BioPharma Dive
